SurgicalAR receives FDA approval

Mark manages all of the content for VRWorldTech. To discuss an idea or pitch a story, drop him a line at editor@vrworldtech.com

Medical imaging company Medivis has received US Food and Drug Administration (FDA) approval for the use of its augmented reality (AR) technology platform, SurgicalAR, in operating theatres.

New York-based Medivis plans to immediately begin rolling out SurgicalAR in the US.

SurgicalAR, released in February, enables surgeons to overlay images directly onto the patient.

According to Medivis, which counts doctors Osamah Choudhry and Christopher Morley as its founders, SurgicalAR allows for “superior precision and real-time decision making” inside and outside of the operating theatre.

“Holographic visualisation is the final frontier of surgical imaging and navigation,” said Choudhry. “The surgical world continues to primarily rely on two-dimensional imaging technology to understand and operate on incredibly complex patient pathology.”

Morley continued: “Medivis introduces advancements in holographic visualisation and navigation to fundamentally advance surgical intervention, and revolutionise how surgeons safely operate on their patients.”

“Achieving this milestone accelerates our mission to improve surgical precision and safety by allowing surgeons to see the invisible.”

FDA approval for SurgicalAR follows the New York medical imaging company’s strategic partnerships with Verizon and Microsoft.

Earlier this year, the company secured $2.3 million in funding, led by Initialized Capital. It also recently released its AnatomyX platform for AR medical training.

Eric Woersching, general partner at Initialized Capital, commented: “Medical imaging for invasive surgical procedures has been waiting for a transformation like this for decades—and we knew from day one that Medivis would be the leader in this emerging space.”

Image credit: Medivis